#1 Clinical Trials Search in Europe

Tozorakimab

Tozorakimab is an investigational drug currently being studied in clinical trials for its potential to treat Chronic Obstructive Pulmonary Disease (COPD) and severe viral lung infections. These trials aim to evaluate the safety and effectiveness of tozorakimab in improving lung function, reducing exacerbations, and enhancing the quality of life for patients with these respiratory conditions. The studies involve different dosing regimens and compare tozorakimab to placebo in addition to standard care treatments.

Table of Contents

What is Tozorakimab?

Tozorakimab, also known as MEDI3506, is a new medication currently being studied for its potential to treat certain respiratory conditions[1]. It belongs to a class of drugs called biologics, which are complex proteins designed to target specific parts of the immune system. Tozorakimab is still in the experimental stage and is not yet approved for general use. Researchers are conducting clinical trials to determine its effectiveness and safety.

What Conditions Does Tozorakimab Treat?

Tozorakimab is being investigated for the treatment of two main conditions:

  • Chronic Obstructive Pulmonary Disease (COPD): This is a long-term lung disease that makes it hard to breathe. It’s often caused by smoking and can lead to frequent flare-ups (exacerbations) that worsen symptoms[2].
  • Viral Lung Infections with Acute Respiratory Failure: This refers to severe lung infections caused by viruses that can lead to difficulty breathing, requiring supplemental oxygen or mechanical ventilation[1].

How is Tozorakimab Administered?

The method of administering Tozorakimab depends on the condition being treated:

  • For COPD: Tozorakimab is given as a subcutaneous injection (under the skin) at regular intervals[2].
  • For viral lung infections: It is administered as a single intravenous (IV) dose[1].

Ongoing Clinical Trials

Several Phase III clinical trials are currently underway to evaluate Tozorakimab:

  • OBERON, TITANIA, and MIRANDA studies: These trials are testing Tozorakimab in patients with COPD who have a history of frequent exacerbations[2].
  • Viral Lung Infection study: This trial is evaluating Tozorakimab in hospitalized patients with viral lung infections requiring supplemental oxygen[1].

Potential Benefits of Tozorakimab

Researchers are studying Tozorakimab to see if it can provide the following benefits:

  • Reduce the frequency of COPD exacerbations (flare-ups)[2]
  • Improve lung function, as measured by FEV1 (the amount of air you can forcefully exhale in one second)[2]
  • Enhance quality of life for COPD patients[2]
  • Decrease the need for rescue medications[2]
  • Prevent death or progression to mechanical ventilation in patients with severe viral lung infections[1]
  • Reduce the duration of hospital stays and time spent in intensive care units (ICU)[1]

Safety Monitoring and Side Effects

As with all new medications, researchers are closely monitoring the safety of Tozorakimab. Some aspects being studied include:

  • Immunogenicity: This refers to the body’s immune response to the drug. Researchers are checking for the presence of anti-drug antibodies, which could potentially reduce the effectiveness of the medication[2].
  • Pharmacokinetics: This involves studying how the drug moves through the body, including its absorption, distribution, and elimination[2].
  • Adverse events: Researchers are carefully tracking any side effects or unexpected reactions that occur during the clinical trials[2].

It’s important to note that as Tozorakimab is still in the testing phase, not all potential side effects may be known. Patients participating in clinical trials are closely monitored by healthcare professionals to ensure their safety.

Aspect Details
Drug Name Tozorakimab (also known as MEDI3506)
Conditions Studied Chronic Obstructive Pulmonary Disease (COPD), Viral Lung Infections
Administration Methods Subcutaneous injection (COPD trials), Intravenous infusion (Viral lung infection trial)
Primary Outcomes Reduction in COPD exacerbations, Prevention of death or progression to IMV/ECMO in viral lung infections
Secondary Outcomes Improvement in lung function (FEV1), Quality of life measures (SGRQ, CAT scores), Time to hospital discharge, Duration of oxygen supplementation
Trial Durations 52 weeks for COPD trials, 28-60 days for viral lung infection trial
Safety Assessments Monitoring for adverse events, Anti-drug antibody development

FAQ

  • What is Tozorakimab? Tozorakimab is an investigational drug being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe viral lung infections. It is administered subcutaneously or intravenously, depending on the specific trial.
  • What conditions is Tozorakimab being tested for? Tozorakimab is primarily being tested for COPD in patients with a history of exacerbations. It is also being studied for its potential to help patients hospitalized with viral lung infections requiring supplemental oxygen.
  • How is Tozorakimab given to patients in the trials? In the COPD trials, Tozorakimab is administered subcutaneously (under the skin) at different doses. For the viral lung infection trial, it is given as a single intravenous (IV) dose.
  • What are the main goals of the Tozorakimab clinical trials? The main goals include evaluating the drug's effectiveness in reducing COPD exacerbations, improving lung function, enhancing quality of life, and for viral lung infections, preventing death or progression to invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
  • How long do the Tozorakimab clinical trials last? The duration varies by trial. The COPD trials last for 52 weeks, with some outcomes measured up to 3 years. The viral lung infection trial measures outcomes over 28 and 60-day periods.

Ongoing Clinical Trials on Tozorakimab

  • Study on Tozorakimab for Adults with Uncontrolled Asthma Using Medium-to-High Dose Inhaled Corticosteroids

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Hungary Italy Spain

  • Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Finland Hungary +5

  • A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Finland France +11

  • Study of Tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Poland Romania

  • Study of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Denmark France Germany Greece +6

Glossary

  • COPD: Chronic Obstructive Pulmonary Disease, a long-term lung condition that causes breathing difficulties and limits airflow from the lungs.
  • Exacerbation: A sudden worsening of COPD symptoms, often requiring additional treatment or hospitalization.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of how much air a person can exhale in one second, used to assess lung function.
  • Subcutaneous: Administered under the skin, typically as an injection.
  • Intravenous (IV): Administered directly into a vein.
  • Placebo: An inactive substance given to some participants in a clinical trial for comparison with the active drug.
  • SGRQ: St. George's Respiratory Questionnaire, a tool used to measure health-related quality of life in patients with respiratory diseases.
  • CAT: COPD Assessment Test, a questionnaire that measures the impact of COPD on a person's life.
  • Invasive Mechanical Ventilation (IMV): A method of artificially assisting or replacing spontaneous breathing, typically involving a tube inserted into the airway.
  • Extracorporeal Membrane Oxygenation (ECMO): A life support machine that oxygenates blood outside the body when the lungs can't perform this function adequately.
  • Anti-drug antibodies: Proteins produced by the immune system in response to a drug, which can potentially affect the drug's effectiveness or safety.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References